Literature DB >> 17182652

Cystic fibrosis mortality and survival in the UK: 1947-2003.

J A Dodge1, P A Lewis, M Stanton, J Wilsher.   

Abstract

Data up to 1995 on the survival of 3-yr cohorts of patients with cystic fibrosis (CF) born in the UK in the period 1968-1992 have previously been published. The present study reports survival data up to the end of 2003 together with a 2003 population estimate. All subjects with CF born in the UK in the period 1968-1992 were identified up to 1997 by active enquiry through recognised CF clinics and other hospital consultants. Information from the death certification authorities up to the end of 2003 was added. Death certificates that could not be matched with UK Cystic Fibrosis Survey records were investigated and the data reconciled. The observed survival up to 2003 of CF patients born in 1978 was 55% for males and 49% for females. For 1988 and 1992 the data were 91 and 88%, and 97 and 96%, respectively. The estimated 2003 mid-year CF population was 8,284. The continuing improvement in survival of cystic fibrosis patients in successive cohorts means that the previous prediction of median survival of >50 yrs of age for individuals born in 2000 continues to look realistic, even in the absence of proven effective therapy aimed at correcting the basic cystic fibrosis defect.

Entities:  

Mesh:

Year:  2006        PMID: 17182652     DOI: 10.1183/09031936.00099506

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  124 in total

1.  Carrier screening in preconception consultation in primary care.

Authors:  Sylvia A Metcalfe
Journal:  J Community Genet       Date:  2011-12-20

2.  Perceived relevance of genetic carrier screening: observations of the role of health-related life experiences and stage of life in decision making.

Authors:  Alison D Archibald; Belinda J McClaren
Journal:  J Community Genet       Date:  2011-11-17

Review 3.  Inhaled antibiotics in cystic fibrosis: what's new?

Authors:  Simon Langton Hewer
Journal:  J R Soc Med       Date:  2012-06       Impact factor: 5.344

4.  Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics.

Authors:  Miquel B Ekkelenkamp; Rafael Cantón; María Díez-Aguilar; Michael M Tunney; Deirdre F Gilpin; Francesca Bernardini; Glenn E Dale; J Stuart Elborn; Jumamurat R Bayjanov; Ad Fluit
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

5.  The future for lung disease in children.

Authors:  Warren Lenney
Journal:  Thorax       Date:  2007-12       Impact factor: 9.139

Review 6.  Cystic fibrosis.

Authors:  Jane C Davies; Eric W F W Alton; Andrew Bush
Journal:  BMJ       Date:  2007-12-15

7.  Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.

Authors:  Thierry Ntimbane; Blandine Comte; Geneviève Mailhot; Yves Berthiaume; Vincent Poitout; Marc Prentki; Rémi Rabasa-Lhoret; Emile Levy
Journal:  Clin Biochem Rev       Date:  2009-11

8.  Cystic Fibrosis: The Mechanisms of Pathogenesis of an Inherited Lung Disorder.

Authors:  Mark T Clunes; Richard C Boucher
Journal:  Drug Discov Today Dis Mech       Date:  2007

9.  Exercise testing in patients with cystic fibrosis-importance of ventilatory parameters.

Authors:  Matthew A Tucker; Nichole Lee; Paula Rodriguez-Miguelez; Jacob Looney; Reva H Crandall; Caralee Forseen; Kathleen T McKie; Ryan A Harris
Journal:  Eur J Appl Physiol       Date:  2018-10-24       Impact factor: 3.078

Review 10.  What's new in cystic fibrosis? From treating symptoms to correction of the basic defect.

Authors:  Marijke Proesmans; François Vermeulen; Kris De Boeck
Journal:  Eur J Pediatr       Date:  2008-04-04       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.